Last reviewed · How we verify
Trastuzumab, Capecitabine and Cisplatin — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Trastuzumab, Capecitabine and Cisplatin (Trastuzumab, Capecitabine and Cisplatin) — Asan Medical Center.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Trastuzumab, Capecitabine and Cisplatin TARGET | Trastuzumab, Capecitabine and Cisplatin | Asan Medical Center | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Trastuzumab, Capecitabine and Cisplatin CI watch — RSS
- Trastuzumab, Capecitabine and Cisplatin CI watch — Atom
- Trastuzumab, Capecitabine and Cisplatin CI watch — JSON
- Trastuzumab, Capecitabine and Cisplatin alone — RSS
Cite this brief
Drug Landscape (2026). Trastuzumab, Capecitabine and Cisplatin — Competitive Intelligence Brief. https://druglandscape.com/ci/trastuzumab-capecitabine-and-cisplatin. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab